176 related articles for article (PubMed ID: 25896113)
21. Tuberculosis, bacillus Calmette-Guérin vaccination, and allergic disease: findings from the International Study of Asthma and Allergies in Childhood Phase Two.
Flohr C; Nagel G; Weinmayr G; Kleiner A; Williams HC; Aït-Khaled N; Strachan DP;
Pediatr Allergy Immunol; 2012 Jun; 23(4):324-31. PubMed ID: 22192272
[TBL] [Abstract][Full Text] [Related]
22. The association between Bacillus Calmette-Guérin vaccination (1331 SSI) skin reaction and subsequent scar development in infants.
Birk NM; Nissen TN; Ladekarl M; Zingmark V; Kjærgaard J; Jensen TM; Jensen SK; Thøstesen LM; Kofoed PE; Stensballe LG; Andersen A; Pryds O; Nielsen SD; Benn CS; Jeppesen DL
BMC Infect Dis; 2017 Aug; 17(1):540. PubMed ID: 28774269
[TBL] [Abstract][Full Text] [Related]
23. Recruiting to Clinical Trials on the Telephone - a randomized controlled trial.
Foss KT; Kjærgaard J; Stensballe LG; Greisen G
Trials; 2016 Nov; 17(1):552. PubMed ID: 27871308
[TBL] [Abstract][Full Text] [Related]
24. Determinants of BCG scarification among children in rural Guinea-Bissau: A prospective cohort study.
Funch KM; Thysen SM; Rodrigues A; Martins CL; Aaby P; Benn CS; Fisker AB
Hum Vaccin Immunother; 2018; 14(10):2434-2442. PubMed ID: 29293396
[TBL] [Abstract][Full Text] [Related]
25. Effects of Bacillus Calmette-Guérin (BCG) vaccination at birth on T and B lymphocyte subsets: Results from a clinical randomized trial.
Birk NM; Nissen TN; Kjærgaard J; Hartling HJ; Thøstesen LM; Kofoed PE; Stensballe LG; Andersen A; Pryds O; Netea MG; Benn CS; Nielsen SD; Jeppesen DL
Sci Rep; 2017 Sep; 7(1):12398. PubMed ID: 28963455
[TBL] [Abstract][Full Text] [Related]
26. Prospective trial of timing of bacillus Calmette-Guérin vaccination in Canadian Cree infants.
Pabst HF; Godel JC; Spady DW; McKechnie J; Grace M
Am Rev Respir Dis; 1989 Oct; 140(4):1007-11. PubMed ID: 2679258
[TBL] [Abstract][Full Text] [Related]
27. Effect of infant immunisation on childhood mortality in rural Bangladesh: analysis of health and demographic surveillance data.
Breiman RF; Streatfield PK; Phelan M; Shifa N; Rashid M; Yunus M
Lancet; 2004 Dec 18-31; 364(9452):2204-11. PubMed ID: 15610807
[TBL] [Abstract][Full Text] [Related]
28. The novel tuberculosis vaccine, AERAS-402, is safe in healthy infants previously vaccinated with BCG, and induces dose-dependent CD4 and CD8T cell responses.
Kagina BM; Tameris MD; Geldenhuys H; Hatherill M; Abel B; Hussey GD; Scriba TJ; Mahomed H; Sadoff JC; Hanekom WA; ; Mansoor N; Hughes J; de Kock M; Whatney W; Africa H; Krohn C; Veldsman A; Kany AL; Douoguih M; Pau MG; Hendriks J; McClainc B; Benko J; Snowden MA; Hokey DA
Vaccine; 2014 Oct; 32(45):5908-17. PubMed ID: 25218194
[TBL] [Abstract][Full Text] [Related]
29. Mycobacterium ulcerans-specific immune response after immunisation with bacillus Calmette-Guérin (BCG) vaccine.
Pittet LF; Tebruegge M; Dutta B; Donath S; Messina N; Casalaz D; Hanekom WA; Britton WJ; Robins-Browne R; Curtis N; Ritz N;
Vaccine; 2021 Jan; 39(4):652-657. PubMed ID: 33371993
[TBL] [Abstract][Full Text] [Related]
30. Bacille-Calmette-Guerin vaccination and the development of allergic disease in children: a randomized, prospective, single-blind study.
Steenhuis TJ; van Aalderen WM; Bloksma N; Nijkamp FP; van der Laag J; van Loveren H; Rijkers GT; Kuis W; Hoekstra MO
Clin Exp Allergy; 2008 Jan; 38(1):79-85. PubMed ID: 17956585
[TBL] [Abstract][Full Text] [Related]
31. Neonatal BCG vaccination has no effect on recurrent wheeze in the first year of life: A randomized clinical trial.
Thøstesen LM; Stensballe LG; Pihl GT; Kjærgaard J; Birk NM; Nissen TN; Jensen AKG; Aaby P; Olesen AW; Jeppesen DL; Benn CS; Kofoed PE
J Allergy Clin Immunol; 2017 Dec; 140(6):1616-1621.e3. PubMed ID: 28347733
[TBL] [Abstract][Full Text] [Related]
32. Safety and immunogenicity of Bacillus Calmette-Guerin vaccine in children born to HIV-1 infected women.
Thaithumyanon P; Thisyakorn U; Punnahitananda S; Praisuwanna P; Ruxrungtham K
Southeast Asian J Trop Med Public Health; 2000 Sep; 31(3):482-6. PubMed ID: 11289006
[TBL] [Abstract][Full Text] [Related]
33. Adverse reactions related to treatment compliance during BCG maintenance therapy for non-muscle-invasive bladder cancer.
Miyazaki J; Hinotsu S; Ishizuka N; Naito S; Ozono S; Akaza H; Nishiyama H
Jpn J Clin Oncol; 2013 Aug; 43(8):827-34. PubMed ID: 23858038
[TBL] [Abstract][Full Text] [Related]
34. Bacillus Calmette-Guérin vaccination for protection against recurrent herpes labialis: a nested randomised controlled trial.
Pittet LF; Moore CL; McDonald E; Barry S; Bonten M; Campbell J; Croda J; Dalcolmo M; Davidson A; Douglas MW; Gardiner K; Gwee A; Jardim B; Lacerda MVG; Lucas M; Lynn DJ; Manning L; de Oliveira RD; Perrett KP; Prat-Aymerich C; Richmond PC; Rocha JL; Rodriguez-Baño J; Warris A; Wood NJ; Messina NL; Curtis N;
EClinicalMedicine; 2023 Oct; 64():102203. PubMed ID: 37719417
[TBL] [Abstract][Full Text] [Related]
35. Influence of Bacillus Calmette-Guèrin vaccination at birth and 2 months old age on the peripheral blood T-cell subpopulations [gamma/delta and alpha-beta T cell].
Taştan Y; Arvas A; Demir G; Alikaşifoğlu M; Gür E; Kiray E
Pediatr Allergy Immunol; 2005 Dec; 16(8):624-9. PubMed ID: 16343082
[TBL] [Abstract][Full Text] [Related]
36. Revaccination with Bacillus Calmette-Guerin (BCG) vaccine does not reduce morbidity from malaria in African children.
Rodrigues A; Schellenberg JA; Roth A; Benn CS; Aaby P; Greenwood B
Trop Med Int Health; 2007 Feb; 12(2):224-9. PubMed ID: 17300629
[TBL] [Abstract][Full Text] [Related]
37. Neonatal vaccination with Bacillus Calmette-Guérin elicits long-term protection in mouse-allergic responses.
Shen H; Huang H; Wang J; Ye S; Li W; Wang K; Zhang G; Wang P
Allergy; 2008 May; 63(5):555-63. PubMed ID: 18307575
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and tolerance of one-third full dose bacillus Calmette-Guérin maintenance therapy every 3 months or 6 months: two-year results of URO-BCG-4 multicenter study.
Pfister C; Kerkeni W; Rigaud J; Le Gal S; Saint F; Colombel M; Guy L; Wallerand H; Irani J; Soulie M;
Int J Urol; 2015 Jan; 22(1):53-60. PubMed ID: 25256813
[TBL] [Abstract][Full Text] [Related]
39. A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus Calmette-Guerin (27 mg) versus very low-dose bacillus Calmette-Guerin (13.5 mg) versus mitomycin C.
Ojea A; Nogueira JL; Solsona E; Flores N; Gómez JM; Molina JR; Chantada V; Camacho JE; Piñeiro LM; Rodríguez RH; Isorna S; Blas M; Martínez-Piñeiro JA; Madero R;
Eur Urol; 2007 Nov; 52(5):1398-406. PubMed ID: 17485161
[TBL] [Abstract][Full Text] [Related]
40. Effectiveness and cost-effectiveness of first BCG vaccination against tuberculosis in school-age children without previous tuberculin test (BCG-REVAC trial): a cluster-randomised trial.
Pereira SM; Barreto ML; Pilger D; Cruz AA; Sant'Anna C; Hijjar MA; Ichihara MY; Santos AC; Genser B; Rodrigues LC
Lancet Infect Dis; 2012 Apr; 12(4):300-6. PubMed ID: 22071248
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
